Gipharma was recently granted marketing authorization in France for Mibitec, a generic version of the widest used SPECT cardiac imaging agent. Mibitec has approved indications for Myocardial perfusion scintigraphy, detection and localization of coronary artery disease and myocardial infarction, assessment of global ventricular function, detection of suspected breast cancer, and localization of hyper-functioning parathyroid tissue.